Elding Larsson, H., Lundgren, M., Jonsdottir, B., Cuthbertson, D., & Krischer, J. (2018). Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatric diabetes, 19(3), 410-419. https://doi.org/10.1111/pedi.12611
Citace podle Chicago (17th ed.)Elding Larsson, Helena, Markus Lundgren, Berglind Jonsdottir, David Cuthbertson, a Jeffrey Krischer. "Safety and Efficacy of Autoantigen‐specific Therapy with 2 Doses of Alum‐formulated Glutamate Decarboxylase in Children with Multiple Islet Autoantibodies and Risk for Type 1 Diabetes: A Randomized Clinical Trial." Pediatric Diabetes 19, no. 3 (2018): 410-419. https://doi.org/10.1111/pedi.12611.
Citace podle MLA (9th ed.)Elding Larsson, Helena, et al. "Safety and Efficacy of Autoantigen‐specific Therapy with 2 Doses of Alum‐formulated Glutamate Decarboxylase in Children with Multiple Islet Autoantibodies and Risk for Type 1 Diabetes: A Randomized Clinical Trial." Pediatric Diabetes, vol. 19, no. 3, 2018, pp. 410-419, https://doi.org/10.1111/pedi.12611.